2014 Program

SUNDAY, JULY 13, 2014

1:30-5:00 pm – Registration and Partnering Desk Open

3:00-5:00 pm – One-to-One Partnering Program (Coles Ballroom)

7:00 pm – Public Lecture: (Gray Ballroom)  – Michael Zigmond, Ph.D. (U. of Pittsburgh) – Returning to our Forebearers: How more exercise can lead to less neurodegeneration 

MONDAY, JULY 14, 2014 

7:30 am – Registration & Partnering Help Desk Open

7:30-8:15 am – Breakfast & Networking

8:15-8:30 am – Opening Remarks (Grey Ballroom)

8:30-9:45 am – SESSION ONE (Gray Ballroom)

  • H. Christian Fibiger, Ph.D. (Medgenesis Therapeutix) – GDNF for the Treatment of Parkinson’s disease
  • Patrick Howson, Ph.D. (Junaxo) – Update on the Neurotrophic Factor Modulator JNX1001 (previously known as Cogane): Results from the CONFIDENT-PD study
  • Michael Zigmond Ph.D. (U. of Pittsburgh) –Protecting Dopamine Neurons with Neurotrophic Factors

9:45 – 10:05 – Networking Break (Coles Ballroom)

10:05 am  – 12:00 – SESSION TWO – Investing in the CNS Sector (Gray Ballroom)

  • Genzyme – G. Andre Turenne, Head of Strategy & Business Development (US)
  • Servier Canada – Laurent Tillement, D.Pharm., Ph.D., Scientific Advisor (Canada)
  • TPBioventures – Tom Blackburn, Ph.D., D.Sc., Founder & CEO  (UK)
  • NEOMED – Philippe Walker, Ph.D., Chief Scientific Officer (Canada)

12:00-1:00 pm – Lunch – Featuring Dr. James Olds, Krasnow Institute for Advanced Learning (Coles Ballroom)

1:00-2:00 pm – One-to-One Partnering Program (Coles Ballroom)

2:00 – 3:15 pm – SESSION THREE (Gray Ballroom)

  • Dale Corbett, Ph.D. (U. of Ottawa) – Neuroregenerative Approaches to Stroke Recovery: BDNF, exercise and stem cell strategies to promote recovery
  • Brandi Ormerod, Ph.D. (U. of Florida) Neuroimmune Signaling, Hippocampal Neurogenesis & Cognition Across Lifespan
  • Marie-Francoise Chesselet, M.D. Ph.D. (UCLA) – Modeling Non-motor Deficits in Parkinson’s disease: Why and How?

3:15 – 3:35 pm – Networking Break (Coles Ballroom)

3:35 – 4:30 pm – SESSION FOUR (Gray Ballroom)

  • Charles K. Meschul, Ph.D.,(Oregon Health & Science University) Genetic Silencing of the Subthalamic Nucleus or TrkB Activation Blocks Dopamine Loss in a Mouse Model of Parkinson’s Disease
  • Thérèse Di Paolo, Ph.D. (Laval University) – Neuroprotection & Rescue in the MPTP Mouse Model of Parkinson’s disease: from Estrogens to Lipids

5:45 pm  – Bus departs Delta Prince Edward for Seaside Lobster Social

 

TUESDAY, JULY 15, 2014 

7:30 am – Registration & Partnering Help Desk Opens

7:30-8:15 am – Breakfast & Networking

8:15-8:30 am – Opening Remarks (Gray Ballroom)

8:30 – 9:45 am – SESSION FIVE – (Gray Ballroom)

  • David Westaway, Ph.D. (U. of Alberta) – Host Protective Response in CNS Prion Diseases: A window on pathogenesis and intervention
  • Niclas Brynne, Ph.D. (MentisCura Diagnostics, Iceland) – EEG as a Marker for Alzheimer’s Disease
  • Nadine Kabbani, Ph.D. (George Mason University) –  Cellular Mechanisms of Synaptic Growth and Regeneration driven by the Alpha 7 Nicotinic Receptor in the Brain  

9:45 – 10:05 am – Networking Break (Coles Ballroom) 

10:05 am – 12:00 pm – SESSION SIX – Investing in the CNS Sector (Gray Ballroom)

  • Eli Lilly Canada – Luc Boulay, Ph.D., Regional MSL Manager (Quebec/Atlantic Canada)
  • Libramen Naturals – Michael Rathbone, M.B. Ch.B., Ph.D., FRCPC (Canada)
  • Somru Bioscience – Mohammed Moin, Vice President of Business Development (Canada)
  • Fundacion MEDINA – Francisca Vicente, Ph.D., Area Head of Screening and Target Validation (Spain)

12:00-1:00 pm – Lunch (Gray Ballroom)

1:00-2:20 pm – One-to-One Partnering Program (Coles Ballroom)

2:20 – 3:10 – SESSION SEVEN (Gray Ballroom)

  • Alfred Maelicke, Ph.D. (Galantos Pharma)  – Phase 1 Clinical Trial Results of the Cognitive Enhancer, Memogain
  • Jackalina Van Kampen, Ph.D. (Neurodyn)  – Disease Modifying Effects of Memogain

3:10 – 3:30 pm – Networking Break (Coles Ballroom)

3:30 – 4:45 pm – SESSION EIGHT (Gray Ballroom)

  • George Robertson, Ph.D. (Dalhousie U.) – Optimization of Mitochrondrial-based Neurotherapeutics
  • Mickael Decressac, Ph.D. (Telethon Institute of Genetics & Medicine, Italy) – Nurr1 in Parkinson’s Disease: From Pathogenesis to Therapeutic Potential
  • Christine Vande Velde, Ph.D. (U. of Montreal) – RNA Granules in ALS Pathogenesis

4: 45 pm – Closing Remarks (Gray Ballroom)